Dr Thomford completed his undergraduate degree in Biochemistry at the University of Ghana. He completed a degree in Master of Philosophy in Medical Biochemistry at the University of Ghana. He worked at the University of Ghana Medical School, Tamale Teaching Hospital and University of Cape Coast School of Medical sciences, teaching. He completed his PhD under the supervision of Professor Collet Dandara in a project involving pharmacogenomics and was awarded a Faculty of Health Sciences and Harry Crossley Foundation (South Africa) research fellowship to conduct research into Latent reversal agents (LRAs) as potential activators of transcriptionally silent HIV. His research interests are in precision and genomic medicine focusing on pharmacogenomics of herb/drug-drug interactions and genomic basis for diseases in African populations and potential therapeutic targets towards personalized/precision medicine. He has published extensively in peer reviewed journals and has over 1000 citations. He reviews for reputable peer-review journals and has supervised postgraduate students (Hons and MSc). He also serves on the editorial boards of Scientific African Journal (Life Science), Frontiers in Medicine (translational medicine) and Systems Medicine. Dr Thomford is a National Research Foundation of South Africa (NRF) Y-rated researcher and an Honorary Research Associate (HRA) of the Division of Human Genetics, Department of Pathology University of Cape Town (January 2020-December 2025). Dr Thomford is the Group Leader/Principal Investigator of the Pharmacogenomics and Genomic Medicine Group at the University of Cape Coast School of Medical Sciences. He is also a Senior Lecturer at the Department of Medical Biochemistry. Dr Thomford has a project tilted "Pharmacomicrobiomics in Malaria-HIV co-infection (MHC) treatment outcome: Finding causal therapeutic variation in Artemisinin-based combination therapy (ACT) and antiretroviral therapy (ART) in a Ghanaian population" that is funded by theEuropean and Developing Countries Clinical Trials Partnership (EDCTP) (TMA2019CDF-2670 — PHARMABIOME.